上海市锦天城律师事务所 关于上海谊众药业股份有限公司 2022 年限制性股票激励计划 作废部分已授予尚未归属限制性股票、 调整授予数量及价格以及预留授予事项 的 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 关于上海谊众药业股份有限公司 2022 年限制性股票激励计划 作废部分已授予尚未归属限制性股票、 调整授予数量及价格以及预留授予事项的法律意见书 本所现根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下 简称"《管理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上 市规则》"）、《科创板上市公司自律监管指南第 4 号——股权激励信息披露》（以 下简称"《监管指南》"）等有关法律、法规、规章和规范性文件的规定以及《上 海谊众药业股份有限公司章程》（以下简称"《公司章程》"）的规定，就公司 2022 年限制性股票激励计划 ...

2、公司本次限制性股票激励计划确定的拟激励对象具备《公司法》、《证券 法》、《管理办法》、《上市规则》等法律、法规和规范性文件及《公司章程》规 定的任职资格，且不存在下列情形：（1）最近 12 个月内被证券交易所认定为不 适当人选；（2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政处罚 或者采取市场禁入措施；（4）具有《公司法》规定的不得担任公司董事、高级 管理人员情形的；（5）法律法规规定不得参与上市公司股权激励的；（6）中国 证监会认定的其他情形。 上海谊众药业股份有限公司监事会 关于公司 2023 年限制性股票激励计划（草案）的 核查意见 上海谊众药业股份有限公司（以下简称"公司"）监事会依据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上 海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创板上市 公司自律监管指南第 4 号——股权激励信息披露》等相关法律、法规及规范性 文件和《 ...

证券代码：688091 证券简称：上海谊众 公告编号：2023-046 上海谊众药业股份有限公司及全资子公司使用部分 闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海谊众药业股份有限公司（以下简称"公司"或"上海谊众"）于 2023 年 8 月 16 日召开了第二届董事会第二次会议、第二届监事会第二次会议，审议通过了《关 于公司及全资子公司使用部分闲置募集资金进行现金管理的议案》。同意公司及全 资子公司在确保不影响募集资金投资项目进度、不影响公司正常生产经营及确保 资金安全的前提下，使用额度不超过人民币 750,000,000.00 元的部分暂时闲置募集 资金进行现金管理，用于购买安全性高、流动性好、满足保本要求的产品（包括但 不限于购买保本型的理财产品、结构性存款、大额存单等），使用期限不超过 12 个 月，在前述额度及使用期限范围内，资金可以循环滚动使用。 一、 募集资金基本情况 经中国证券监督管理委员会于 2021 年 8 月 3 日发布的《关于同意上海谊众药 业股份有限公司首次公 ...

证券代码：688091 证券简称：上海谊众 公告编号：2023-054 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司股权激励 管理办法》（以下简称"《管理办法》"）的有关规定，并受上海谊众药业股份有限公 司（以下简称"公司"）其他独立董事的委托，独立董事胡改蓉女士作为征集人， 就公司拟于 2023 年 9 月 8 日召开的 2023 年第二次临时股东大会审议的股权激励 相关议案向公司全体股东征集投票权。 一、 征集人的基本情况、对表决事项的表决意见及理由 （一）征集人的基本情况 上海谊众药业股份有限公司 关于独立董事公开征集委托投票权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次征集投票权的征集人为公司现任独立董事胡改蓉女士，其基本情况如下： 胡改蓉女士，1977 年 11 月出生，中国国籍，无境外永久居留权，法学博士， 教授，博士生导师，兼职律师。2003 年 7 月至 2009 年 6 月，任职西北政法大学教 师；2009 年 7 月至今，任职华东政法大学教师。兼任中国法 ...

上海谊众药业股份有限公司 2022 年限制性股票激励计划预留授予部分 激励对象名单（预留授予日） 一、 预留授予部分分配情况 | 职务 | 获授的股票数量（万股） | 占预留授予股票总数的比例 | 占目前总股本的比例 | | --- | --- | --- | --- | | 中层骨干人员 | 22 | 100% | 0.1390% | | （1 人） | | | | 二、核心骨干人员名单 | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 1 刘秀立 | 营销核心骨干人员 | 1：刘秀立为公司营销中心核心骨干人员，主要负责营销中心整体商务工作的运营与指定区 域销售工作的管理。经公司全面考核，刘秀立在分析市场趋势与竞争对手、制定销售策略 与销售计划等工作上做出了重要贡献。 上海谊众药业股份有限公司董事会 2023 年 8 月 16 日 1 ...

证券代码：688091 证券简称：上海谊众 公告编号：2023-050 上海谊众药业股份有限公司关于调整 2022 年限制性股票激励计划相关事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海谊众药业股份有限公司（以下简称"公司"）于 2023 年 8 月 16 日召开 了第二届董事会第二次会议、第二节监事会第二次会议，审议通过了《关于调整 公司 2022 年限制性股票激励计划相关事项的议案》，调整后的情况如下： 6、2023 年 8 月 16 日，公司召开第二届董事会第二次会议、第二届监事会第 二次会议，审议通过了《关于调整公司 2022 年限制性股票激励计划相关事项的议 案》。公司董事会依据 2022 年第四次临时股东大会的授权，对公司 2022 年限制性 股票激励计划相关事项进行调整。公司独立董事发表了同意的独立意见。 5、2022 年 12 月 21 日，公司召开第一届董事会第十七次会议与第一届监事会 第十四次会议，审议通过了《关于向激励对象首次授予限制性股票的议案》。公司 独立董事对该 ...

证券代码：688091 证券简称：上海谊众 公告编号：2023-049 上海谊众药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 9 月 18 日（星期一）下午 14:00-15:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 9 月 11 日（星期一）至 9 月 15 日(星期五)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 info@yizhongpharma.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 上海谊众药业股份有限公司（以下简称"公司"）已于 2023 年 8 月 18 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半 年度经营成果、财务状 ...

一、 说明会类型 证券代码：688091 证券简称：上海谊众 公告编号：2023-033 上海谊众药业股份有限公司关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 05 月 31 日(星期三) 下午 14:00-15:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 24 日(星期三) 至 05 月 30 日(星期 二)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 info@yizhongpharma.com 进行提问。公司将在说明会 上对投资者普遍关注的问题进行回答。 上海谊众药业股份有限公司（以下简称"公司"）已于 2023 年 3 月 1 日发布公司 2022 年年度报告，并于 2023 年 4 月 26 日发布公司 2023 年一季报。为便 ...

Financial Performance - The company's operating revenue for Q1 2023 reached ¥92,399,635.15, representing a year-on-year increase of 169.06%[5] - The net profit attributable to shareholders was ¥55,025,022.44, reflecting a significant increase of 78.98% compared to the same period last year[10] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥47,798,545.07, up by 106.73% year-on-year[5] - Basic and diluted earnings per share were both ¥0.38, marking a year-on-year increase of 31.03%[6] - Total operating revenue for Q1 2023 reached ¥92,399,635.15, a significant increase of 169.1% compared to ¥34,342,009.48 in Q1 2022[20] - Net profit for Q1 2023 was ¥55,025,022.44, representing an increase of 79.0% from ¥30,744,481.85 in Q1 2022[21] Cash Flow - The net cash flow from operating activities amounted to ¥29,835,404.92, an increase of 40.52% from the previous year[10] - Cash inflow from operating activities in Q1 2023 totaled ¥65,986,940.77, up from ¥30,312,144.85 in Q1 2022[23] - The net cash flow from operating activities for Q1 2023 was $29,835,404.92, an increase from $21,232,493.06 in Q1 2022, reflecting a growth of approximately 40.5%[24] - The net increase in cash and cash equivalents for Q1 2023 was $52,444,543.03, a decrease from $175,686,256.57 in Q1 2022, showing a decline of about 70%[25] - The ending balance of cash and cash equivalents was $758,691,049.55, up from $286,116,789.52 in the previous year, indicating an increase of approximately 164.5%[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,418,079,852.04, up 4.69% from the end of the previous year[6] - As of March 31, 2023, the total current assets amounted to RMB 1,261,329,406.58, an increase from RMB 1,199,711,000.68 as of December 31, 2022, reflecting a growth of approximately 5.15%[14] - The total liabilities included accounts payable of RMB 14,098,066.64, down from RMB 21,534,488.09, indicating a decrease of approximately 34.5%[16] - The company's total liabilities as of Q1 2023 amounted to ¥37,251,952.05, an increase from ¥35,415,374.82 in the previous year[20] Research and Development - The company's R&D investment totaled ¥2,602,773.90, which is an increase of 78.71% compared to the same period last year[6] - Research and development expenses for Q1 2023 were ¥2,602,773.90, an increase of 78.5% from ¥1,456,396.10 in Q1 2022[20] - R&D investment accounted for 2.82% of operating revenue, a decrease of 1.42 percentage points year-on-year[6] Employee Compensation - The company reported a significant increase in employee compensation payable, which rose to RMB 5,198,401.73 from RMB 3,080,074.55, reflecting an increase of about 68.7%[16] - The total cash outflow for employee compensation and related payments was $10,688,523.68, significantly higher than $4,476,278.42 in Q1 2022, marking an increase of about 138.5%[24] Other Information - The significant increase in revenue and profit was primarily driven by the continuous growth in sales volume of core products[10] - The company has not disclosed any new product or technology developments in this quarter[14] - There are no significant mergers or acquisitions reported during this period[14] - The company has not provided specific future guidance or market expansion strategies in the current report[14] - Financial expenses for Q1 2023 showed a net income of -¥6,723,815.08, compared to -¥1,234,872.41 in Q1 2022, indicating improved financial management[20]

Financial Performance - The company reported a net profit attributable to shareholders of 116,464,091.82 yuan after offsetting previous years' losses, with a distributable profit of 104,817,682.64 yuan after deducting statutory surplus reserves[12]. - The company reported a total profit of 40,068,130.32, with a significant increase in non-operating income amounting to 18,320,075.31[32]. - The company reported a significant increase in sales volume of its core product, paclitaxel micelles, contributing to the revenue growth[52]. - The company achieved a net profit attributable to shareholders of 142.85 million yuan, compared to a loss of 3.99 million yuan in the previous year, marking a turnaround to profitability[74]. - The company's operating revenue for 2022 was ¥235,957,004.22, a significant increase of 5,686.75% compared to ¥4,077,536.27 in 2021[51]. - The net cash flow from operating activities reached ¥110,784,705.94, compared to a negative cash flow of ¥48,784,143.53 in the previous year[51]. - The company reported a net profit of 102.79 million yuan after deducting non-recurring gains and losses, compared to a loss of 17.73 million yuan in the previous year[74]. - The company reported a significant increase in fair value changes from financial assets, amounting to 12,892,744.49, indicating strong market performance[32]. - The net assets attributable to shareholders increased by 12.22% to ¥1,319,178,266.25 at the end of 2022[51]. - The weighted average return on equity increased to 11.46%, up 12.3 percentage points from -0.84% in 2021[74]. Dividend and Share Capital - A cash dividend of 3.00 yuan per 10 shares (including tax) is proposed, totaling 43,166,400 yuan, which accounts for 30.22% of the net profit attributable to shareholders for the year[13]. - The total share capital increased from 105.8 million shares to 143.888 million shares following a capital reserve conversion plan approved by the board[4]. - The company plans to increase its total share capital from 143,888,000 shares to 158,276,800 shares by issuing 1 additional share for every 10 shares held, totaling 14,388,800 new shares[38]. - The company has reported a distributable profit of 104,817,682.64 CNY after deducting the statutory surplus reserve, indicating sufficient conditions for cash dividends in 2022[191]. - The total share capital will increase from 10,580,000 shares to 14,388,800 shares due to a capital reserve conversion plan, with a distribution of 3.6 shares for every 10 shares held[186]. Risk Management - The company has detailed potential risks in its operations, which are discussed in the management's analysis section of the report[3]. - The company does not foresee any significant investment plans or major cash expenditures in the near term, indicating a stable financial outlook[12]. - The company has no significant risks that materially affect its production and operations during the reporting period[3]. - The company emphasized the importance of risk awareness regarding forward-looking statements in its annual report, advising investors to be cautious[39]. Research and Development - The company is engaged in ongoing research and development, focusing on clinical trials to validate the efficacy and safety of its products[47]. - The company's R&D investment accounted for 3.36% of operating revenue, reflecting a commitment to innovation and product development[85]. - The company is actively advancing its product pipeline, developing innovative high-tech drugs targeting prostate and pancreatic cancers[92]. - The research and development strategy focuses on expanding the indications for its core product, the injectable paclitaxel polymer micelle, and developing targeted conjugate drugs[100]. - The company has applied for and authorized 2 invention patents during the reporting period[162]. Marketing and Sales Strategy - The company is focused on expanding its product offerings, particularly in the area of paclitaxel formulations, which are critical for cancer treatment[19]. - The marketing strategy emphasizes brand establishment and product clinical positioning, aiming to create a differentiated advantage for paclitaxel as a leading brand[88]. - The company has successfully listed its products in 27 provinces and cities across the country, focusing on outpatient DTP pharmacies for sales[77]. - The company plans to continue enhancing its marketing team and establishing long-term incentive mechanisms to strengthen its marketing capabilities[76]. - The sales strategy focuses on global promotion, with a primary emphasis on self-operated sales domestically and significant partnerships with strong listed companies to accelerate market entry[119]. Corporate Governance - The company has committed to ensuring the authenticity and completeness of its annual report, with all board members and senior management assuming legal responsibility[9]. - The company emphasizes strict compliance with corporate governance and internal control management to ensure high-quality development[99]. - The company is committed to continuous improvement in corporate governance and compliance with regulatory requirements to ensure sustainable development[122]. - The board of directors held 7 meetings, the supervisory board held 7 meetings, and 5 shareholder meetings during the reporting period, all in compliance with relevant laws and regulations[122]. - The independent directors participated actively in board meetings, with no instances of consecutive absences[144]. Employee and Talent Development - The company has a total of 243 employees, with 125 in sales, 34 in production, and 28 in research[181]. - The company has a total of 5 employees with doctoral degrees and 13 with master's degrees[182]. - The company has implemented a structured salary system that includes basic salary, position salary, and allowances[182]. - The company is committed to a talent development plan that combines internal training and external recruitment to cultivate professionals aligned with corporate values[93]. - The company has implemented a scientific and reasonable equity incentive and compensation system to enhance talent utilization[147].